New pharmacological treatment options for irritable bowel syndrome with constipation

Expert Opin Emerg Drugs. 2015;20(4):625-36. doi: 10.1517/14728214.2015.1105215. Epub 2015 Nov 7.


Introduction: Constipation predominant irritable bowel syndrome (IBS-C) is a common disorder and accounts for a large number of ambulatory visits. Sensory abnormalities, that is, presence of abdominal pain and discomfort, distinguish IBS-C from chronic idiopathic constipation.

Area covered: This review focuses on the pharmacology, efficacy, safety, and future of prucalopride, YKP-10811, DSP-6952, dexloxiglumide, linaclotide, plecanatide, tenapanor, and elobixibat.

Expert opinion: It is now well established that treatment focusing only on bowel transit provides incomplete relief to patients with IBS-C. Improved understanding of pathophysiology of IBS-C has led to use of sensory end points like complete spontaneous bowel movements and the FDA combined end point (abdominal pain and complete spontaneous bowel movements) in clinical trials. A number of drugs are in development and provide hope for this challenging group of patients. However, because of recent failures secondary to ineffectiveness and/or adverse events, we cautiously await how clinical data play out in larger studies and in clinical practice.

Keywords: DSP-6952; YKP-10811; bile acid transport inhibitor; cholecystokinin receptor antagonist; dexloxiglumide; elobixibat; guanylate cyclase-C agonist; linaclotide; plecanatide; serotonin agonist; sodium–proton exchange inhibitor; tenapanor.

Publication types

  • Review

MeSH terms

  • Abdominal Pain / etiology
  • Animals
  • Constipation / drug therapy*
  • Constipation / etiology
  • Drug Design
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / pharmacology
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Irritable Bowel Syndrome / drug therapy*
  • Irritable Bowel Syndrome / physiopathology


  • Gastrointestinal Agents